Skip to main content
Top
Published in: Current Colorectal Cancer Reports 3/2013

01-09-2013 | Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer

Authors: Jan Franko, Charles D. Goldman, Kiran K. Turaga

Published in: Current Colorectal Cancer Reports | Issue 3/2013

Login to get access

Abstract

Peritoneal carcinomatosis from colorectal cancer is increasingly recognized as a special form of metastatic disease. This review focuses on the efficacy of systemic chemotherapy in the setting of peritoneal carcinomatosis. Peritoneal carcinomatosis-affected individuals succumb to their disease earlier than those without known carcinomatosis, with an approximately 30 % reduction in overall survival. Modern cytotoxic combination chemotherapy incorporating oxaliplatin and irinotecan has resulted in marked improvement of overall survival among carcinomatosis patients, but not to the same extent as for non-carcinomatosis patients. Biologicals are also associated with increased overall survival, but still seem to underperform in the carcinomatosis patient. Efficacy of 5FU monotherapy seems negligible. Evidence suggests future trials should be stratified by peritoneal carcinomatosis status. Complementary benefits of systemic chemotherapy and cytoreductive surgical approaches warrant further studies.
Literature
2.
go back to reference Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol. 2007;14(12):3460–71. doi:10.1245/s10434-007-9557-7.PubMedCrossRef Varghese S, Burness M, Xu H, Beresnev T, Pingpank J, Alexander HR. Site-specific gene expression profiles and novel molecular prognostic factors in patients with lower gastrointestinal adenocarcinoma diffusely metastatic to liver or peritoneum. Ann Surg Oncol. 2007;14(12):3460–71. doi:10.​1245/​s10434-007-9557-7.PubMedCrossRef
3.
go back to reference Levine EA, Blazer 3rd DG, Kim MK, Shen P, Stewart JH, Guy C, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599–606. doi:10.1016/j.jamcollsurg.2011.12.028. discussion −7.PubMedCrossRef Levine EA, Blazer 3rd DG, Kim MK, Shen P, Stewart JH, Guy C, et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg. 2012;214(4):599–606. doi:10.​1016/​j.​jamcollsurg.​2011.​12.​028. discussion −7.PubMedCrossRef
4.
go back to reference Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol. 2001;8(8):632–7.PubMedCrossRef Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol. 2001;8(8):632–7.PubMedCrossRef
6.
go back to reference Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.PubMedCrossRef Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124–32.PubMedCrossRef
7.
go back to reference •• Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. doi:10.1200/JCO.2003.04.187. First and only completed randomized trail focusing on patients with isolated peritoneal carcinomatosis—comparing best systemic chemotherapy available at that time (5FU, minority patients also irinotecan) with or without cytoreductive surgery plus intraperitoneal chemotherapy. Patients randomized to systemic chemotherapy plus cytoreduction survived longer on intention-to-treat analysis (HR = 0.55).PubMedCrossRef •• Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. doi:10.​1200/​JCO.​2003.​04.​187. First and only completed randomized trail focusing on patients with isolated peritoneal carcinomatosis—comparing best systemic chemotherapy available at that time (5FU, minority patients also irinotecan) with or without cytoreductive surgery plus intraperitoneal chemotherapy. Patients randomized to systemic chemotherapy plus cytoreduction survived longer on intention-to-treat analysis (HR = 0.55).PubMedCrossRef
8.
go back to reference Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. doi:10.1200/JCO.2008.19.7160.PubMedCrossRef Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5. doi:10.​1200/​JCO.​2008.​19.​7160.PubMedCrossRef
9.
go back to reference Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh 3rd HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62. doi:10.1002/cncr.25116.PubMedCrossRef Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh 3rd HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116(16):3756–62. doi:10.​1002/​cncr.​25116.PubMedCrossRef
10.
go back to reference •• Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–7. doi:10.1200/JCO.2011.37.1039. Largest available secondary analysis of systemic chemotherapy trials with attention to peritoneal carcinomatosis. Patients with peritoneal carcinomatosis benefited from systemic chemotherapy, but survived shorter (HR = 1.4).PubMedCrossRef •• Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30(3):263–7. doi:10.​1200/​JCO.​2011.​37.​1039. Largest available secondary analysis of systemic chemotherapy trials with attention to peritoneal carcinomatosis. Patients with peritoneal carcinomatosis benefited from systemic chemotherapy, but survived shorter (HR = 1.4).PubMedCrossRef
11.
go back to reference Pelz JO, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689. doi:10.1186/1471-2407-10-689.PubMedCrossRef Pelz JO, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;10:689. doi:10.​1186/​1471-2407-10-689.PubMedCrossRef
12.
go back to reference Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15. doi:10.1002/jso.21169.PubMedCrossRef Pelz JO, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15. doi:10.​1002/​jso.​21169.PubMedCrossRef
13.
go back to reference Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer. 2012;11(4):247–54. doi:10.1016/j.clcc.2012.06.004.PubMedCrossRef Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer. 2012;11(4):247–54. doi:10.​1016/​j.​clcc.​2012.​06.​004.PubMedCrossRef
14.
go back to reference Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999;79(11–12):1800–5. doi:10.1038/sj.bjc.6690287.PubMed Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer. 1999;79(11–12):1800–5. doi:10.​1038/​sj.​bjc.​6690287.PubMed
15.
go back to reference •• Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617–23. doi:10.1016/j.ejso.2012.03.008. European secondary analysis of systemic chemotherapy trials with attention to peritoneal carcinomatosis. Patients with peritoneal carcinomatosis benefited from systemic chemotherapy, but survived shorter. Outcomes were comparable with those in North American study in Ref. [10].PubMedCrossRef •• Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38(7):617–23. doi:10.​1016/​j.​ejso.​2012.​03.​008. European secondary analysis of systemic chemotherapy trials with attention to peritoneal carcinomatosis. Patients with peritoneal carcinomatosis benefited from systemic chemotherapy, but survived shorter. Outcomes were comparable with those in North American study in Ref. [10].PubMedCrossRef
16.
go back to reference • Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705. doi:10.1002/bjs.8679. Detailed analysis of peritoneal carcinomatosis incidence and development after diagnosis of any stage CRC in population.PubMedCrossRef • Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705. doi:10.​1002/​bjs.​8679. Detailed analysis of peritoneal carcinomatosis incidence and development after diagnosis of any stage CRC in population.PubMedCrossRef
18.
go back to reference Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JO. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432–9. doi:10.1038/bjc.2013.82. Kerscher AG, Chua TC, Gasser M, Maeder U, Kunzmann V, Isbert C, Germer CT, Pelz JO. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer. 2013;108(7):1432–9. doi:10.​1038/​bjc.​2013.​82.
19.
go back to reference • Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717–25. doi:10.1002/ijc.25596. Detailed analysis of peritoneal carcinomatosis outcomes in defined population and changes over time. Peritoneal carcinomatosis was associated with poorer outcome.PubMedCrossRef • Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717–25. doi:10.​1002/​ijc.​25596. Detailed analysis of peritoneal carcinomatosis outcomes in defined population and changes over time. Peritoneal carcinomatosis was associated with poorer outcome.PubMedCrossRef
20.
go back to reference Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol. 2005;12(10):765–77. Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol. 2005;12(10):765–77.
21.
go back to reference Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856–62. doi:10.1038/bjc.2011.19.PubMedCrossRef Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer. 2011;104(5):856–62. doi:10.​1038/​bjc.​2011.​19.PubMedCrossRef
22.
go back to reference Helyer LK, Law CH, Butler M, Last LD, Smith AJ, Wright FC. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol. 2007;14(4):1264–71. doi:10.1245/s10434-006-9303-6.PubMedCrossRef Helyer LK, Law CH, Butler M, Last LD, Smith AJ, Wright FC. Surgery as a bridge to palliative chemotherapy in patients with malignant bowel obstruction from colorectal cancer. Ann Surg Oncol. 2007;14(4):1264–71. doi:10.​1245/​s10434-006-9303-6.PubMedCrossRef
23.
go back to reference Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.PubMedCrossRef Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.PubMedCrossRef
24.
go back to reference Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124–9.PubMed Gilly FN, Carry PY, Sayag AC, Brachet A, Panteix G, Salle B, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124–9.PubMed
25.
go back to reference Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22(10):2250–6. doi:10.1093/annonc/mdq762.PubMedCrossRef Klaver YL, Lemmens VE, Creemers GJ, Rutten HJ, Nienhuijs SW, de Hingh IH. Population-based survival of patients with peritoneal carcinomatosis from colorectal origin in the era of increasing use of palliative chemotherapy. Ann Oncol. 2011;22(10):2250–6. doi:10.​1093/​annonc/​mdq762.PubMedCrossRef
26.
go back to reference • Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308–17. Detailed analysis of efficacy of 5FU chemotherapy in mCRC demonstrating significant outcome variability. Information on peritoneal carcinomatosis was missing among 30 % cases, but peritoneal carcinomatosis was associated with poorer outcome.PubMedCrossRef • Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308–17. Detailed analysis of efficacy of 5FU chemotherapy in mCRC demonstrating significant outcome variability. Information on peritoneal carcinomatosis was missing among 30 % cases, but peritoneal carcinomatosis was associated with poorer outcome.PubMedCrossRef
27.
go back to reference Folprecht G, Köhne C-H, Lutz M. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. In: Ceelen WP, editor. Peritoneal carcinomatosis: a multidisciplinary approach. Cancer treatment and research, vol 134: Springer, New York; 2007. p. 425–40. Folprecht G, Köhne C-H, Lutz M. Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. In: Ceelen WP, editor. Peritoneal carcinomatosis: a multidisciplinary approach. Cancer treatment and research, vol 134: Springer, New York; 2007. p. 425–40.
28.
go back to reference Zani S, Papalezova K, Stinnett S, Tyler D, Hsu D, Blazer 3rd DG. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. J Surg Oncol. 2012. doi:10.1002/jso.23222.PubMed Zani S, Papalezova K, Stinnett S, Tyler D, Hsu D, Blazer 3rd DG. Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. J Surg Oncol. 2012. doi:10.​1002/​jso.​23222.PubMed
30.
go back to reference Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23(36):9441–2. doi:10.1200/JCO.2005.04.479.PubMedCrossRef Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005;23(36):9441–2. doi:10.​1200/​JCO.​2005.​04.​479.PubMedCrossRef
31.
go back to reference Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37. doi:10.1200/JCO.2004.05.113.PubMedCrossRef Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37. doi:10.​1200/​JCO.​2004.​05.​113.PubMedCrossRef
32.
go back to reference Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18(6):1560–7. doi:10.1245/s10434-010-1522-1.PubMedCrossRef Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18(6):1560–7. doi:10.​1245/​s10434-010-1522-1.PubMedCrossRef
33.
go back to reference Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7.PubMedCrossRef Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–7.PubMedCrossRef
34.
go back to reference Köhne C-H, Bokemeyer C, Folprecht G, Sartorius U, Schlichting M, Rougier PR et al. Cetuximab plus chemotherapy in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: a pooled analysis of the CRYSTAL and OPUS studies. J Clin Oncol. 2012;30(suppl 4):abstr 96. Köhne C-H, Bokemeyer C, Folprecht G, Sartorius U, Schlichting M, Rougier PR et al. Cetuximab plus chemotherapy in patients with liver-limited or non-liver-limited KRAS wild-type colorectal metastases: a pooled analysis of the CRYSTAL and OPUS studies. J Clin Oncol. 2012;30(suppl 4):abstr 96.
35.
go back to reference Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13. doi:10.1245/s10434-007-9487-4.PubMedCrossRef Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13. doi:10.​1245/​s10434-007-9487-4.PubMedCrossRef
37.
go back to reference Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. doi:10.1200/JCO.2004.10.012.PubMedCrossRef Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92. doi:10.​1200/​JCO.​2004.​10.​012.PubMedCrossRef
38.
go back to reference Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231(4):449–56.PubMedCrossRef Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: a multicenter phase III trial. Ann Surg. 2000;231(4):449–56.PubMedCrossRef
39.
go back to reference Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 2005;6(7):459–68. doi:10.1016/S1470-2045(05)70222-9.PubMedCrossRef Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol. 2005;6(7):459–68. doi:10.​1016/​S1470-2045(05)70222-9.PubMedCrossRef
41.
go back to reference Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006;6:162. doi:10.1186/1471-2407-6-162.PubMedCrossRef Pelz JO, Doerfer J, Dimmler A, Hohenberger W, Meyer T. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations. BMC Cancer. 2006;6:162. doi:10.​1186/​1471-2407-6-162.PubMedCrossRef
42.
go back to reference Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.PubMedCrossRef Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004;11(2):178–86.PubMedCrossRef
43.
go back to reference Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic Intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. doi:10.1245/s10434-008-9966-2.PubMedCrossRef Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic Intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. doi:10.​1245/​s10434-008-9966-2.PubMedCrossRef
45.
go back to reference Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818–24. doi:10.1245/s10434-007-9348-1.PubMedCrossRef Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14(6):1818–24. doi:10.​1245/​s10434-007-9348-1.PubMedCrossRef
46.
go back to reference Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21. doi:10.1002/ijc.25423.PubMedCrossRef Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21. doi:10.​1002/​ijc.​25423.PubMedCrossRef
Metadata
Title
Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer
Authors
Jan Franko
Charles D. Goldman
Kiran K. Turaga
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Colorectal Cancer Reports / Issue 3/2013
Print ISSN: 1556-3790
Electronic ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0173-6

Other articles of this Issue 3/2013

Current Colorectal Cancer Reports 3/2013 Go to the issue

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

The Role of Adjuvant Therapy in the Elderly

Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

Optimum Duration of Metastatic Colorectal Cancer Treatment

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Functions and Clinical Implications of Autocrine VEGF Signaling in Colorectal Cancer

Adjuvant Therapy for Colon Cancers (AB Benson III and A de Gramont, Section Editors)

Clinical Reasons for Initiation of Adjuvant Phase III Trials on Colon Cancer

Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options

Therapeutic Approaches to Metastatic Colorectal Cancers (E Díaz-Rubio, Section Editor)

The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine